Factors that enhance hypercoagulability following BMT may have a pathogenetic role in VOD. To investigate the relevance of hemostatic parameters for the development of VOD, we prospectively measured protein C, protein S, antithrombin III (AT III), von Willebrand factor, and factor VIII in 50 consecutive patients undergoing allogeneic BMT. Each parameter was determined before conditioning, on day 0 of BMT and weekly for 3 weeks, and patients were monitored prospectively for the occurrence of VOD. VOD occurred in 26 patients at median post-BMT day 8.5 (range, day ؊2 to 17). Thirteen patients had mild, 10 had moderate and three had severe VOD. No coagulation parameters were significantly different at the baseline or on day 0 of BMT between patients with no/mild VOD and moderate to severe VOD. On day 7 and thereafter, levels of protein C and AT III were significantly lower in patients with moderate to severe VOD when compared to patients with no/mild VOD. Levels of protein C and AT III decreased before the clinical onset of VOD in patients with moderate to severe VOD. Early post-BMT reduction of these parameters may indicate the development of moderate to severe VOD.
Typical clinical features of VOD include hyperbilirubinemia, painful hepatomegaly and fluid retention. Histologically, VOD is characterized by deposition of factor VIII and fibrinogen in the subenthothelial zones of affected venules and by necrosis of hepatocytes in zone 3 of the liver acinus. 3 Endothelial damage induced by high-dose chemoradiation therapy is believed to be the key event in the pathogenesis of VOD. This endothelial injury triggers the coagulation cascade, induces thrombosis of the hepatic venules and eventually leads to fibrous obliteration of the affec-ted venules. Factors that enhance hypercoagulability following BMT may have a pathogenetic role in the development of VOD. 4 In fact, a decrease in the natural anticoagulants such as protein C, 5, 6 protein S 5 and antithrombin III (AT III) 6 as well as an increase in plasma fibrinogen 4 and von Willebrand factor (vWF) 7 have been observed after BMT. Several investigators have reported that these hemostatic derangements may have pathogenetic relevance for the occurrence of VOD. [8] [9] [10] In this study, we prospectively measured the levels of protein C, protein S (total and free), AT III, vWF and factor VIII in 50 consecutive patients undergoing allogeneic BMT. We investigated the predictive value of these hemostatic parameters for the development of VOD after allogeneic BMT. Changes in the hemostatic parameters were correlated with subsequent clinical course particularly with regard to the development and severity of VOD.
Patients and methods

Patients
All patients who underwent allogeneic BMT in the Asan Medical Center from October 1995 to February 1998 were enrolled into the study. The following preparative regimens were used: BUCY (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg) for leukemia/MDS, BUCY plus etoposide for CML in blastic phase, BUCY plus melphalan for neuroblastoma, and CY-ATG (cyclophosphamide 200 mg/kg and antithymocyte globulin 90 mg/kg) for SAA. All patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD). For the prevention of VOD, heparin was administered to those patients who received the BUCY-based regimen, at a rate of 100 units/kg/day from day Ϫ7 to day 30. Heparin was discontinued if there was clinically significant bleeding or the PTT exceeded 1.2 times the upper limit of control.
Diagnosis of hepatic VOD
All enrolled patients were monitored prospectively for the occurrence of VOD. A diagnosis of VOD was made according to clinical criteria, 11 as having two of the following before day 20 post-transplant: (1) hyperbilirubinemia (bilirubin у2.0 mg/dl or 34.2 mol/l), (2) painful hepatomegaly, and (3) unexplained weight gain (Ͼ2% from baseline), no other explanation for these signs and symptoms being present at the time of diagnosis. Severity of VOD was classified into mild, moderate or severe. 1 Patients who met the criteria for VOD, but who were not treated and whose illness was self-limited, were considered to have mild VOD. Those whose VOD resolved but who received treatment such as diuretics for fluid retention or narcotic analgesics for painful hepatomegaly, were considered to have moderate VOD. Patients who died of VOD or whose VOD did not resolve by 100 days post-transplant were considered to have severe VOD. Onset of VOD was defined as the day on which total serum bilirubin exceeded 2.0 mg/dl (34.2 mol/l) or body weight increased more than 2% above the baseline.
Assays of hemostatic parameters
Changes in protein C, protein S (total and free), AT III, vWF antigen and factor VIII were monitored in all enrolled patients. Each hemostatic parameter was determined before preparative chemotherapy, on the day of marrow infusion (day 0), and on days 7, 14 and 21. Protein C was measured by a commercially available enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies (AsserachromProtein C; Stago, Asnières, France). Protein S (total and free) and vWF antigen were also determined by a commercially available ELISA using monoclonal antibodies (Asserachrom-Total Protein S, Asserachrom-Free Protein S, Asserachrom-vWF; Stago). Antithrombin III was measured by chromogenic assay (Stachrome-AT III; Stago). Factor VIII was measured using Stago-Deficient VIII (Stago).
Statistical analysis
Individual characteristics were analyzed using the 2 test for association with development of VOD. The multiple logistic regression model was used for subsequent multivariate analysis. The one-way ANOVA test was used to analyze differences in the values of each hemostatic parameter at different times between patients with no VOD, mild VOD and moderate to severe VOD. Changes of each hemostatic parameter from the baseline values were analyzed using the paired t-test. Probabilities of engraftment and survival were calculated using the Kaplan-Meier method and compared by log-rank analysis.
Results
Patient characteristics
Fifty patients, 30 males and 20 females, were enrolled in the study. The median age of the patients was 32.5 years (range, . The indication for BMT was acute myelocytic leukemia (AML) in 22 patients, acute lymphoblastic leukemia (ALL) in five, chronic myelocytic leukemia (CML) in nine, severe aplastic anemia (SAA) in nine, myelodysplastic syndrome (MDS) in four, and neuroblastoma in one. At the time of BMT 13 patients had high-risk features: AML in second remission (two patients), CML in blastic phase (one patient), refractory anemia of excess blasts (RAEB) (two patients), RAEB in transformation (one patient), chemotherapy-resistant neuroblastoma (one patient), and heavily transfused SAA (six patients). Fortyseven patients received allogeneic marrow grafts from HLA-identical siblings, one patient from an HLA-mismatched sibling, and two from HLA-phenotypically identical unrelated donors. Heparin was administered for prophylaxis of VOD in 40 patients. In 24 patients, heparin was discontinued before day 10 post-transplant because of PTT prolongation and/or evidence of bleeding.
Of the 50 patients enrolled, 26 developed VOD (52.0%). Table 1 illustrates the patient characteristics which were putative risk factors for the development of VOD. In univariate analysis, male sex (P = 0.049) and a larger amount of red cell transfusion prior to BMT (P = 0.048) were significant risk factors for VOD. However, these factors lost their significance after multivariate analysis using a multiple logistic regression model (P = 0.054 for male sex, P = 0.390 for red cell transfusion).
Clinical features of the patients with VOD
Of 26 patients with VOD, 13 (50.0%) had mild, 10 (38.0%) had moderate and three (12.0%) had severe VOD. Seventeen patients (65.4%) satisfied all three clinical criteria for VOD. The frequencies of clinical features associated with VOD were as follows: unexplained weight gain in 25 (96.2%), hyperbilirubinemia in 23 (88.5%), painful hepatomegaly in 21 (80.8%), ascites in 13 (50%), peripheral edema in four (15.4%) and azotemia in four (15.4%). The median onset of VOD was day 8.5 (range, day Ϫ2 to day 17) in all patients with VOD, day 11 (range, day 1 to day 17) in patients with mild VOD, and day 8 (range, day Ϫ2 to day 13) in patients with moderate to severe VOD. The median duration of VOD was 27 days (range, 10 to 103 days). All patients with VOD received supportive care only, without specific treatment such as recombinant tissue plasminogen activator. Clinical outcomes according to the occurrence and severity of VOD were analyzed in terms of engraftment probabilities, transfusion requirements, and mortality at day 100 post-transplant (Table 2) . Platelet engraftment, which was defined as a platelet count of over 20 × 10 6 /l without platelet transfusions, was significantly slower in patients with VOD and severity of VOD correlated with degree of delay in platelet engraftment (P = 0.005). Patients with VOD also required a larger amount of platelet transfusion (P = 0.011). Mortality rates at day 100 post-transplant were 5.0, 7.7 and 25.0%, respectively for patients with no VOD, mild VOD and moderate to severe VOD (P = 0.116).
Natural anticoagulants (protein C, protein S and AT III)
As shown in Table 3 , none of the parameters were significantly different at the baseline or on day 0 of BMT between patients with and without subsequent VOD. On day 7, the mean plasma levels of protein C and AT III were significantly lower in patients with moderate to severe VOD when compared to patients with no/mild VOD (P = 0.007 for protein C, P = 0.034 for AT III). These differences were also significant on day 14 (P Ͻ 0.000 for protein C, P = 0.030 for AT III) and day 21 (P = 0.001 for protein C, P Ͻ 0.000 for AT III). Mean plasma levels of protein C and AT III decreased with time between day 7 and day 21 in the patients with moderate to severe VOD, and was virtually parallel without significant change in patients with no/mild VOD (Figures 1 and 2) . The mean plasma levels of total and free protein S showed no significant difference at five different time points between patients with no/mild VOD and with moderate to severe VOD, except for the day 14 level of total protein S in mild VOD patients. When compared with the baseline, a significant decrease in mean plasma level of natural anticoagulants was observed in patients with moderate to severe VOD. Protein C level decreased significantly from the baseline on day 14 (91 vs 53%, P = 0.038) and day 21 (91 vs 49%, P = 0.041) in patients with moderate to severe VOD (Figure 1 ). Changes in AT III were similar to those in protein C (Figure 2) . The mean plasma level of AT III on day 21 fell significantly when compared to the baseline level in patients with moderate to severe VOD (85 vs 68%, P Ͻ 0.001). On day 14 and day 21, total protein S levels significantly decreased from baseline levels in patients with moderate to severe VOD (92 vs 73%, P = 0.048 for day 14, 92 vs 74%, P = 0.046 for day 21). Free protein S levels also fell compared to the baseline levels in patients with moderate to severe VOD on day 21 (88 vs 66%, P = 0.002).
In patients with no/mild VOD, mean plasma levels of natural anticoagulants did not change significantly from the baseline throughout the monitoring period.
Although the administration of heparin may decrease the level of AT III, there was no difference in AT III levels whether patients received heparin prophylaxis or not. 
von Willebrand factor and factor VIII
The mean plasma levels of vWF and factor VIII showed no significant difference at each time point between patients with no/mild VOD and moderate to severe VOD. There was a significant rise in the mean plasma levels of vWF from baseline levels in patients with no/mild VOD, but, these changes of vWF were not significant in patients with moderate to severe VOD ( Figure 3 ).
Discussion
A hypercoagulable state, which has been observed in many patients after BMT, may occur in the face of decrease of natural anticoagulants 5, 6 (protein C, protein S and AT III), increase of procoagulants 4, 7 (factor VIII, fibrinogen and von Willebrand factor), or changes in fibrinolytic parameters [12] [13] [14] (tissue plasminogen activator, plasminogen activator inhibitor-1). Gordon et al 15 found that deficiencies in protein C persisted for at least 100 days after BMT in nearly one-quarter of patients and those patients undergoing BMT might be at prolonged risk of thrombotic complications. This hypercoagulability has been implicated in the development of VOD after BMT. 16 Although Faioni et al 8 suggested that protein C levels before the start of conditioning would indicate patients at risk for developing VOD, many others including our study have failed to demonstrate that pre-conditioning levels of various coagulation parameters can predict for the development of VOD in patients undergoing BMT. However, decrease of natural anticoagulants and change of fibrinolytic activity following BMT have been shown to be relevant to occurrence of VOD in several reports. 9, 13, 14, [17] [18] [19] Specifically, protein C and AT III decreased usually at 0-14 days after marrow infusion in patients with VOD. 9, 13, 17 Plasminogen activator inhibitor-1 has been reported to identify VOD in patients with posttransplant hyperbilirubinemia. 19 In our study, we prospectively examined the levels of natural anticoagulants protein C, protein S (free and total) and AT III as well as von Willebrand factor antigen and functional activity of factor VIII in 50 consecutive patients undergoing allogeneic BMT. Each parameter was measured before conditioning, on day 0 of BMT, and weekly thereafter for 3 weeks. The levels of protein C and AT III fell significantly on day 7 and decreased over time in patients with moderate to severe VOD when compared to the patients with no/mild VOD. In addition, there were significant reductions in natural anticoagulants (protein C, total and free protein S and AT III) after BMT from baseline levels in patients with moderate to severe VOD. These findings may simply have resulted from the decrease of hepatic synthetic function associated with VOD, although the changes in coagulation parameters may indicate that the natural anticoagulants have some pathogenetic role in the development of VOD. Regardless of whether decreased levels of natural anticoagulants are a cause or result of VOD, they are likely to aggravate its clinical effects. Because the median onset of VOD in patients with moderate to severe VOD was day 8 post-transplant, levels of protein C and AT III decreased before clinical onset of the disease. Thus, early post-BMT reduction in protein C and AT III may predict for the occurrence of moderate to severe VOD. In patients with moderate to severe VOD, the time to platelets of over 20 × 10 6 /l without platelet support was significantly delayed and platelet requirements were significantly larger when compared to the patients with no/mild VOD. Mortality rate of day 100 post-transplant was also higher, although not statistically significant. Thus, the predictive value of protein C and AT III for the development of moderate to severe VOD may have clinical implications. Morris et al 20 administered AT III to 10 patients with AT III levels less than 88% and life-threatening single or multiorgan dysfunction, and they observed that the probability of death due to organ dysfunction was significantly less when compared to an historical control group. In patients with decreased levels of protein C or AT III after BMT, early therapeutic intervention such as protein C and AT III concentrate may prevent the development of moderate to severe VOD and improve clinical outcome. Also, the role of hemostatic abnormalities in VOD may be underscored by reports of successful treatment with thrombolytic agenst such as tissue plasminogen activator. 21 Endothelial cell activation may play a role in VOD after BMT and vWF antigen levels have been used as a marker of endothelial cell activation. Collins et al 7 measured vWF antigen levels in 72 patients during the first 6 weeks posttransplant. There was a significant rise in vWF antigen in uncomplicated patients, but the changes in vWF antigen in three patients with VOD did not show a consistent pattern. In our study, vWF increased significantly after BMT from the baseline level in patients with no/mild VOD, but changes of vWF after BMT were not significant in patients with moderate to severe patients. Furthermore, there was no significant difference in vWF levels between patients with no, mild and moderate to severe VOD. When taken together these results suggest that severity of VOD does not correlate with the degree of disruption of endothelial cells, and vWF cannot be used to predict for the development of VOD.
Shulman et al 3 showed that factor VIII and fibrinogen within the subendothelial zones of affected terminal hepatic venules seem to be a major component in the obstruction of sinusoidal blood flow in patients with VOD. We measured the levels of factor VIII activity in plasma, but there was no significant change in levels of factor VIII before and after BMT in either patients with or without VOD.
In summary, levels of protein C and AT III decreased before clinical onset of moderate to severe VOD. Early post-BMT reduction of these parameters may indicate those likely to develop moderate to severe VOD. Further studies are warranted to assess the role of protein C or AT III concentrates in prevention or treatment of VOD after BMT.
